Sycrest 5 mg sublingual tablets

Spain
Brand name Sycrest 5 mg sublingual tablets
Form tablets, sublingual
Active substance / Dosage
Prescription type Prescription Only Medicine
Registration number 10640002
Manufacturer Organon N.V.
Sycrest 5 mg sublingual tablets tablets, sublingual

Package leaflet: Information for the user

Introduction

Package leaflet: information for the patient

Sycrest 5 mg sublingual tablets

Sycrest 10 mg sublingual tablets

asenapine

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only, and you must not give it to others, even if they have the same symptoms as you, because it may harm them.
  • If you experience any adverse reactions, consult your doctor, pharmacist or nurse, even if they are adverse reactions not listed in this leaflet. See section 4.

Leaflet contents

  1. What Sycrest is and what it is used for
  2. What you need to know before taking Sycrest
  3. How to take Sycrest
  4. Possible side effects
  5. How to store Sycrest
  6. Contents of the pack and other information

1. What Sycrest is and what it is used for

Sycrest contains the active substance asenapine. This medicine belongs to a group of medicines called antipsychotics. Sycrest is used to treat moderate to severe manic episodes associated with bipolar I disorder in adults. Antipsychotic medicines affect the chemical substances that enable communication between nerve cells (neurotransmitters). Brain disorders such as bipolar I disorder may be due to an imbalance of certain chemicals in the brain, such as dopamine and serotonin, and these imbalances may cause some of the symptoms you are experiencing. The exact way this medicine works is not known, but it is believed to help restore the balance of these chemicals.

Manic episodes associated with bipolar I disorder are a condition characterized by symptoms such as feeling overly well, having excessive energy, needing much less sleep than usual, speaking very rapidly with many ideas, and sometimes extreme irritability.

2. What you need to know before starting Sycrest

Do not take Sycrest

If you are allergic to asenapine or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before taking Sycrest.

Sycrest has not been studied in elderly patients with dementia. However, elderly patients treated with other types of similar medicines may have an increased risk of stroke or death. Sycrest has not been approved for the treatment of elderly patients with dementia and is not recommended for use in this particular group of patients.

Sycrest may cause a drop in blood pressure. In the early stages of treatment, some people may faint, especially when getting up from a lying or sitting position. This usually resolves on its own, but if it does not, inform your doctor, as a dose adjustment may be needed.

Asenapine may cause drowsiness, sudden drops in blood pressure when standing up, dizziness, and changes in your ability to move and balance, which may lead to falls and, consequently, fractures or other traumatic injuries. Patients at risk of falling should be evaluated before prescribing asenapine.

Contact your doctor immediately if you experience

  • involuntary rhythmic movements of the tongue, mouth, or face. Discontinuation of Sycrest treatment may be necessary.
  • fever, severe muscle stiffness, sweating, or decreased level of consciousness (a condition known as "neuroleptic malignant syndrome"). Immediate medical treatment may be required.

Before taking Sycrest, check with your doctor or pharmacist:

  • if you have ever been diagnosed with a condition characterized by high body temperature and muscle rigidity (also known as neuroleptic malignant syndrome).
  • if you have ever experienced abnormal movements of the tongue or face (tardive dyskinesia).
  • You should be aware that both conditions may be caused by this type of medicine.
  • if you have heart disease or are being treated for a heart condition that may make you prone to low blood pressure
  • if you have diabetes or are at risk of developing diabetes
  • if you have Parkinson's disease or dementia
  • if you have epilepsy (seizures)
  • if you experience difficulty swallowing (dysphagia)
  • if you have severe liver problems. If so, you must not take Sycrest
  • if you have problems with body temperature regulation
  • if you have suicidal thoughts
  • if you have abnormally high levels of prolactin in the blood (hyperprolactinemia)

Be sure to inform your doctor if you are in any of these situations so that they can adjust your dose or monitor you for a period of time. Also, consult your doctor immediately if any of these conditions develop or worsen while you are using Sycrest.

Children and adolescents

The use of Sycrest is not recommended in patients under 18 years of age.

Other medicines and Sycrest

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines. Some medicines may reduce or increase the effect of Sycrest.

If you are taking other medicines, Sycrest should be taken last.

You must inform your doctor if you are taking antidepressant medicines (specifically fluvoxamine, paroxetine, or fluoxetine), as it may be necessary to adjust your dose of Sycrest or your dose of the antidepressant.

You must inform your doctor if you are taking medicines for Parkinson's disease (such as levodopa), as this medicine may make them less effective.

Sycrest acts mainly in the brain, so there may be interactions with other medicines (or with alcohol) that also act on the brain due to additive effects on brain function.

Sycrest may lower blood pressure, so caution is advised when Sycrest is taken together with other medicines that lower blood pressure.

Taking Sycrest with food, drinks, and alcohol

Do not eat or drink for 10 minutes after taking this medicine.

You should avoid drinking alcohol while taking this medicine.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you might be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.

Do not take Sycrest during pregnancy unless your doctor tells you to. If you are taking this medicine and become pregnant or plan to become pregnant, consult your doctor as soon as possible to determine whether you can continue taking Sycrest.

The following symptoms may occur in newborn babies of mothers who have been treated with Sycrest during the third trimester of pregnancy (last three months of pregnancy): tremors, muscle stiffness and/or weakness, drowsiness, agitation, breathing difficulties, and feeding problems. If your baby develops any of these symptoms, contact your doctor.

Do not breastfeed while taking Sycrest.

Driving and using machines

Sycrest may cause drowsiness or sedation. Therefore, make sure your concentration and alertness are not affected before driving or operating machinery.

3. How to take Sycrest

Follow exactly the instructions for using this medicine as given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

The recommended dose is one 5 mg or 10 mg sublingual tablet twice daily. One dose should be taken in the morning and another dose in the evening.

Instructions for use

Sycrest is for sublingual use.

Sycrest is not recommended if you are unable to take the tablet as described below. If you are unable to take this medicine as described below, treatment may not be effective for you.

  • Do not remove the sublingual tablet from the blister pack until the time of administration.
  • Handle the tablet with dry hands.
  • Do not push the tablet through the blister. Do not cut or tear the blister.
  • Peel back the coloured tab (Figure 1).
  • Carefully remove the tablet (Figure 2). Do not crush the tablet.
  • To ensure optimal absorption, place the tablet under the tongue and wait until it has completely dissolved (Figure 3). The tablet will dissolve in saliva within seconds.
  • Do not swallow or chew the tablet.
  • Do not eat or drink for 10 minutes after taking the tablet.

Two hands holding and separating a small medical container with a blue top and a gray base for

Two hands holding and pressing a circular medical device with a red arrow indicating the direction of downward pressure

Profile of a person inserting a tablet into an open mouth, hand holding the medication near the lips

Figure 1

Figure 2

Figure 3

If you take more Sycrest than you should

If you take too much Sycrest, contact a doctor immediately. Take the medicine with you. In case of overdose, you may feel drowsy or tired, have abnormal body movements, problems standing or walking, feel dizzy due to a drop in blood pressure, and feel agitated and confused.

If you forget to take Sycrest

Do not take a double dose to make up for missed doses. If you forget to take a dose, take your next dose as usual. If you forget to take two or more doses, consult your doctor or pharmacist.

If you stop taking Sycrest

If you stop treatment with Sycrest, you will lose the effects of this medicine. You should not stop treatment with this medicine unless your doctor tells you to, as your symptoms may return.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

Serious adverse effects have been reported with this medicine. Seek immediate medical attention if you experience any of the following symptoms:

  • allergic reactions (usually involve a combination of effects such as difficulty breathing or swallowing, swelling of the face, lips, tongue or throat, rash, itching, and increased heart rate)
  • sudden increase in body temperature, with sweating, rapid pulse, severe muscle rigidity, confusion and variable blood pressure, which may lead to coma
  • seizures, fits or convulsions
  • fainting
  • falls may occur as a result of one or more adverse effects such as: drowsiness, sudden drop in blood pressure when standing up, dizziness, and changes in your ability to move and in balance.

Immediately inform your doctor if you have:

  • signs of increased blood sugar levels such as excessive thirst, hunger or urination, weakness, or worsening of diabetes
  • snake-like movements of the tongue, or other uncontrolled movements of the tongue, mouth, cheeks, jaw, which may progress to arms and legs

Other adverse effects reported with this medicine are:

Very common adverse effects (may affect more than 1 in 10 people)

  • anxiety
  • somnolence

Common adverse effects (may affect up to 1 in 10 people)

  • weight gain
  • increased appetite
  • slow or sustained muscle contractions
  • restlessness
  • involuntary muscle contractions
  • slow movements, tremor
  • sedation
  • dizziness
  • nausea
  • change in taste
  • sensation of numbness in the tongue or mouth
  • increased saliva (drooling)
  • muscle stiffness
  • fatigue
  • increased liver protein levels

Uncommon adverse effects (may affect up to 1 in 100 people)

  • abnormal muscle movements: a group of symptoms known as extrapyramidal symptoms, which may include one or more of the following: abnormal muscle, tongue or jaw movements, slow or sustained muscle contractions, muscle spasms, tremor (agitation), abnormal eye movements, involuntary muscle contractions, slow movements or restlessness
  • unpleasant sensation in the legs (also known as restless legs syndrome)
  • difficulty speaking
  • abnormally slow or fast heartbeat
  • heart block
  • abnormal electrocardiogram (prolongation of QT interval)
  • drop in blood pressure upon standing
  • low blood pressure
  • tingling in the tongue or mouth
  • swollen or painful tongue
  • difficulty swallowing
  • ulcers, pain, redness, swelling and blisters inside the mouth
  • sexual dysfunction
  • absence of regular menstrual periods

Rare adverse effects (may affect up to 1 in 1,000 people)

  • changes in white blood cell (leukocyte) levels
  • difficulty focusing vision
  • blood clots in blood vessels leading to the lungs, causing chest pain and difficulty breathing
  • muscle disease manifested by unexplained pain
  • breast enlargement in men
  • leakage of milk or fluids from the breast

Reporting of adverse effects

If you experience any type of adverse effect, talk to your doctor, pharmacist or nurse, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Sycrest

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the blister and on the outer packaging. The expiry date refers to the last day of the month indicated.

Store this medicine in its original packaging to protect it from light and moisture.

No special storage temperature is required for this medicine.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of any packaging and medicines you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Sycrest

  • The active substance is asenapine.
  • Each 5 mg sublingual tablet of Sycrest contains 5 mg of asenapine.
  • Each 10 mg sublingual tablet of Sycrest contains 10 mg of asenapine.
  • The exact amount is shown on your Sycrest packaging.
  • The other components are gelatin and mannitol (E-421).

Appearance of the product and contents of the pack

The 5 mg sublingual tablets are round, white to off-white tablets, marked with "5" on one side.

The 10 mg sublingual tablets are round, white to off-white tablets, marked with "10" on one side.

The sublingual tablets are supplied in peelable blisters containing 10 tablets each. Packs contain 20, 60 or 100 tablets.

Some pack sizes may not be marketed.

Marketing Authorization Holder

N.V. Organon
Kloosterstraat 6
NL-5349 AB Oss
The Netherlands

Manufacturer

Organon Heist bv
Industriepark 30
2220 Heist-op-den-Berg, Belgium

For further information regarding this medicinal product, please contact the local representative of the Marketing Authorization Holder:

Belgium/Belgium/Belgium

Organon Belgium

Tel/Tel: 0080066550123 (+32 2 2418100)

[email protected]

Lithuania

Organon Pharma B.V. Lithuania branch

Tel.: +370 52041693

[email protected]

Text in Cyrillic characters with the name Organon, Bulgarian phone number, and contact email address for the office in Bulgaria

Luxembourg/Luxembourg

Organon Belgium

Tel/Tel: 0080066550123 (+32 2 2418100)

[email protected]

Czech Republic

Organon Czech Republic s.r.o.

Tel: +420 277 051 010

[email protected]

Hungary

Organon Hungary Kft.

Tel.: +36 1 766 1963

[email protected]

Denmark

Organon Denmark ApS

Tlf: +45 4484 6800

[email protected]

Malta

Organon Pharma B.V., Cyprus branch

Tel: +356 2277 8116

[email protected]

Germany

Organon Healthcare GmbH

Tel.: 0800 3384 726 (+49 (0) 89 2040022 10)

[email protected]

Netherlands

N.V. Organon

Tel: 00800 66550123 (+32 2 2418100)

[email protected]

Estonia

Organon Pharma B.V. Estonian RO

Tel: +372 66 61 300

[email protected]

Norway

Organon Norway AS

Tlf: +47 24 14 56 60

[email protected]

Greece

BIANEΞ Α.Ε.

Tel: +30 210 80091 11

[email protected]

Austria

Organon Healthcare GmbH

Tel: +49 (0) 89 2040022 10

[email protected]

Spain

Organon Salud, S.L.

Tel: +34 91 591 12 79

[email protected]

Poland

Organon Polska Sp. z o.o.

Tel.: +48 22 306 57 64

[email protected]

France

Organon France

Tel: +33 (0) 1 57 77 32 00

Portugal

Organon Portugal, Sociedade Unipessoal Lda.

Tel: +351 218705500

[email protected]

Croatia

Organon Pharma d.o.o.

Tel: +385 1 638 4530

[email protected]

Romania

Organon Biosciences S.R.L.

Tel: +40 21 527 29 90

[email protected]

Ireland

Organon Pharma (Ireland) Limited

Tel: +353 15828260

[email protected]

Slovenia

Organon Pharma B.V., Oss, branch Ljubljana

Tel: +386 1 300 10 80

[email protected]

Iceland

Vistor ehf.

Tel: +354 535 7000

Slovakia

Organon Slovakia s.r.o.

Tel: +421 2 44 88 98 88

[email protected]

Italy

Organon Italia S.r.l.

Tel: +39 06 90259059

[email protected]

Finland

Organon Finland Oy

Tel/Puh: +358 (0) 29 170 3520

[email protected]

Cyprus

Organon Pharma B.V., Cyprus branch

Tel: +357 22866730

[email protected]

Sweden

Organon Sweden AB

Tel: +46 8 502 597 00

[email protected]

Latvia

Commercial representative of “Organon Pharma B.V.” in Latvia

Tel: +371 66968876

[email protected]

Date of the most recent review of this leaflet: {month/YYYY}.

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.